Charging for investigational drugs under an investigational new drug application. Final rule.
The Food and Drug Administration (FDA) is amending its investigational new drug application (IND) regulation concerning charging patients for investigational new drugs. This final rule revises the charging regulation to clarify the circumstances in which charging for an investigational drug in a clinical trial is appropriate, to set forth criteria for charging for an investigational drug for the different types of expanded access for treatment use described in the agency's final rule on expanded access for treatment use of investigational drugs published elsewhere in this issue of the Federal Register, and to clarify what costs can be recovered for an investigational drug. This final rule will permit charging for a broader range of uses than was explicitly permitted previously.
D002986:Clinical Trials as Topic / Q000191:economics / Q000331:legislation & jurisprudence; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational / Q000191:economics* / Q000627:therapeutic use; D005249:Fees and Charges / Q000941:ethics / Q000331:legislation & jurisprudence*; D006297:Health Services Accessibility / Q000191:economics / Q000331:legislation & jurisprudence; D006801:Humans; D017387:Investigational New Drug Application / Q000191:economics* / Q000331:legislation & jurisprudence; D007880:Legislation, Drug / Q000191:economics*; D014481:United States; D014486:United States Food and Drug Administration
D015507:Drugs, Investigational